The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial
Open accessAbstract
Importance: The use of benzodiazepines to control agitation in delirium in the last days of life is controversial. Objective: To compare the effect of lorazepam vs placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium in the setting of advanced cancer. Design, Setting, and Participants: Single-center, double-blind, parallel-group, randomized clinical trial conducted at an acute palliative care unit at MD Anderson Cancer Center, Texas, enrolling 93 patients with advanced cancer and agitated delirium despite scheduled haloperidol from February 11, 2014, to June 30, 2016, with data collection completed in October 2016. Interventions: Lorazepam (3 mg) intravenously (n = 47) or placebo (n = 43) in addition to haloperidol (2 mg) intravenously upon the onset of an agitation episode. Main Outcomes and Measures: The primary outcome was change in Richmond Agitation-Sedation Scale (RASS) score (range, -5 [unarousable] to 4 [very agitated or combative]) from baseline to 8 hours after treatment administration. Secondary end points were rescue neuroleptic use, delirium recall, comfort (perceived by caregivers and nurses), communication capacity, delirium severity, adverse effects, discharge outcomes, and overall survival. Results: Among 90 randomized patients (mean age, 62 years; women, 42 [47%]), 58 (64%) received the study medication and 52 (90%) completed the trial. Lorazepam + haloperidol resulted in a significantly greater reduction of RASS score at 8 hours (-4.1 points) than placebo + haloperidol (-2.3 points) (mean difference, -1.9 points [95% CI, -2.8 to -0.9]; P < .001). The lorazepam + haloperidol group required less median rescue neuroleptics (2.0 mg) than the placebo + haloperidol group (4.0 mg) (median difference, -1.0 mg [95% CI, -2.0 to 0]; P = .009) and was perceived to be more comfortable by both blinded caregivers and nurses (caregivers: 84% for the lorazepam + haloperidol group vs 37% for the placebo + haloperidol group; mean difference, 47% [95% CI, 14% to 73%], P = .007; nurses: 77% for the lorazepam + haloperidol group vs 30% for the placebo + haloperidol group; mean difference, 47% [95% CI, 17% to 71%], P = .005). No significant between-group differences were found in delirium-related distress and survival. The most common adverse effect was hypokinesia (3 patients in the lorazepam + haloperidol group [19%] and 4 patients in the placebo + haloperidol group [27%]). Conclusions and Relevance: In this preliminary trial of hospitalized patients with agitated delirium in the setting of advanced cancer, the addition of lorazepam to haloperidol compared with haloperidol alone resulted in a significantly greater reduction in agitation at 8 hours. Further research is needed to assess generalizability and adverse effects. Trial Registration: clinicaltrials.gov Identifier: NCT01949662.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sessler, C. N., Gosnell, M. S., Grap, M. J., Brophy, G. M., O'Neal, P. V., Keane, K. A., Tesoro, E. P., & Elswick, R. K. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2107138 · Cited by 3,695
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
The Edmonton Symptom Assessment System 25 years later: past, present, and future developments
Hui, D., & Bruera, E. (2017) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2016.10.370 · Cited by 795
Self-citationLonergan, E., Luxenberg, J., & Areosa Sastre, A. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006379.pub3 · Cited by 223
Cited by
Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Swarm, R. A., Paice, J. A., Anghelescu, D. L., Are, M., Bruce, J. Y., Buga, S., Chwistek, M., Cleeland, C., Craig, D., Gafford, E., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0038 · Cited by 621
Models of Palliative Care Delivery for Patients With Cancer
Hui, D., & Bruera, E. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.18.02123 · Cited by 323
Self-citationWu, Y.-C., Tseng, P.-T., Tu, Y.-K., Hsu, C.-Y., Liang, C.-S., Yeh, T.-C., Chen, T.-Y., Chu, C.-S., Matsuoka, Y. J., Stubbs, B., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.4365 · Cited by 148
Metadata
- Authors
- Hui, D., Frisbee-Hume, S., Wilson, A., Dibaj, S. S., Nguyen, T., De La Cruz, M., Walker, P., Zhukovsky, D. S., Delgado-Guay, M., Vidal, M., Epner, D., Reddy, A., Tanco, K., Williams, J., Hall, S., Liu, D., Hess, K., Amin, S., Breitbart, W., & Bruera, E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2017-09-19
- Volume
- 318
- Issue
- 11
- Pages
- 1047
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2754657935
- Cited by
- 207
- References
- 4
- FWCI
- 19.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2017.11468
- The paper
- Hui, D., Frisbee-Hume, S., Wilson, A., Dibaj, S. S., Nguyen, T., De La Cruz, M., Walker, P., Zhukovsky, D. S., Delgado-Guay, M., Vidal, M., Epner, D., Reddy, A., Tanco, K., Williams, J., Hall, S., Liu, D., Hess, K., Amin, S., Breitbart, W., & Bruera, E. (2017). Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2017.11468
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.